Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine.
One hundred and fifty-three patients, forty-eight to ninety-seven years old, were included in a double-blind placebo-controlled investigation of the usefulness of hydroxychloroquine sulphate for the prevention of deep venous thrombosis in patients with fractures of the hip, pelvis, or thoracolumbar spine. The results indicated that this drug can reduce the number of thrombeombolic complications significantly (p less than 0.005), a finding that corresponds to the results obtained with other drugs such as coumarin derivatives or  dextran 70.
D000368:Aged; D005260:Female; D005340:Fibrinogen; D050723:Fractures, Bone / Q000150:complications*; D025981:Hip Injuries; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D008159:Lumbar Vertebrae / Q000293:injuries; D008297:Male; D008875:Middle Aged; D010384:Pelvic Bones / Q000293:injuries; D010690:Phlebography; D011877:Radionuclide Imaging; D013904:Thoracic Vertebrae / Q000293:injuries; D013924:Thrombophlebitis / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control*
D006886:Hydroxychloroquine; D005340:Fibrinogen